Founding Partner,
Admitted to the Paris and Geneva Bars
a.carrel@mce-carrel.fr
+33 6 11 89 64 05
MCE CARREL Paris / MCE LEGAL Lausanne

LinkedIn Alexandra CARREL

Alexandra Carrel founder of Cabinet Carrel, now known as MCE Carrel, in 2014 in Paris and Geneva. Previously, she worked at international law firms in London, Geneva, and Paris for more than 10 years and then served as General Counsel and Secretary General of Inserm Transfert, the TTO of Inserm. 

In parallel with her work in France, Alexandra Carrel joined the Swiss law firm MCE Avocats in 2022, bringing her expertise in life sciences, new technologies, and energy. Over the course of her career, she has developed a unique knowledge in innovation and technology transfer, particularly in the development of products for health & beauty (drugs, nutrients, cosmetics), in the green chemistry and renewable energy sectors, as well as for AI and robotics.

Her expertise in intellectual property, Swiss and French business law, and her knowledge of US law enable her to handle complex international transactions and assist her clients from the creation and protection of their innovations to the outsourcing of their technologies, assets, or business. Alexandra is ranked a top tiers lawyer for pharma deals in France and Switzerland.

Alexandra Carrel is also a member of the board of directors of KetoSwiss and the board of trustees of the Nexus Foundation in Switzerland.

• Advising biotechnology, medtech, and deeptech companies on collaboration, co-development option, and/or licensing agreements with industrial partners (mid-sized companies, large industrial groups).
• Advising biotechnology, medtech, and deeptech companies on the development (including multicenter clinical trials), manufacturing, production, and distribution of innovative products, as well as negotiating the corresponding contracts.
• Advising on private equity, M&A or asset disposal transactions on product & IP strategy and corresponding financial terms.
• Audit of contracts and intellectual property assets for investment rounds or acquisitions.
• Negotiating on behalf of innovative companies cross-licensing agreements, co-development agreements and joint ventures with international industrial partners.
• Negotiating drug manufacturing agreements and clinical trial agreements for biotech companies.
• Negotiating collaboration, licensing, and framework agreements for biotechnology companies with academic institutions.

Main transactions (2026-2025): Negotiated a territorial exclusive licence agreement for Biodol with Kyorin. Acted as outside General Counsel for ImCheck from Series A to exit. Negotiated a global licensing agreement for Syndivia with GSK. Negotiated two co-development agreements for Vet-Horus with US industrial partners. Negotiated a territorial exclusive option agreement for Biodol with Kyorin. Negotiated intellectual property aspects of Dianosic’s agreement with Aptar. Assisted Superbranche in raising several million dollars in international equity round. Negotiated for Vect-Horus a global exclusive license agreement with Novo Nordisk and a global exclusive license agreement with Ionis. Negotiated or renegotiated in-license agreements or co-ownership and exploitation agreements for innovative companies with US, Swiss and French non-profit Institutions and their TTOs.

Recent Litigations: Represented researchers in a dispute with their licensee. Represented a biotech company in a dispute with its manufacturer following the shutdown of a production site (claim >10M). Represented a biotech company building a pilot plant in a dispute with a supplier. Represented a biotechnology company in a dispute with its manufacturer for defective batches (claim >5M). Represented a licensee in a litigation with its licensor (claim >10M).